Press Conference, Forum, Cancer Prevention Coalition and National Family Forum Coalition, Room HC-6, U.S. Congress, Washington, D.C., March 14, 1995
The biosynthetic growth hormone, rBGH, has been available for commercial use by dairy farmers since February 4th following FDA's prior approval of the Monsanto product. More recently, the FDA has warned dairy farmers, retailers, and processors against the use of hormone-free labels to distinguish milk from untreated.
- MOUNTING EVIDENCE LINKS CONSUMPTION OF rBGH AND DAIRY PRODUCTS TO INCREASED BREAST CANCER RISK.
- THE RISK OF BREAST CANCER IS DUE TO SUSTAINED AND ELEVATED LEVELS IN MILK OF THE POTENT GROWTH FACTOR IGF-1.
- THE INFANT IS LIKELY TO BE PARTICULARLY SENSITIVE TO THE FUTURE CARCINOGENIC EFFECTS OF IGF-1.
In a February 14th letter to the Food and Drug Administration (FDA) and other government agencies, Dr. Samuel Epstein, Chair of the Cancer Prevention Coalition "expressed grave concerns about the risks of breast cancer from consumption of rBGH milk." The letter, which summarized the underlying scientific evidence, has received no response from the FDA, the National Cancer Institute or Members of Congress as of March 9th.
This information further confirms the national Family Farm Coalition's position that the rBGH should never have been approved by the FDA in view of evidence on explicit adverse public health and veterinary effects.